Home

Pharmacology

Parkinson's Disease

Read time: 3 min

Congress highlights

Managing strategies for Parkinson’s disease: A multipronged approach for a multifaceted illness

Parkinson’s disease is characterized by motor symptoms and a wide range of non-motor symptoms...

Parkinson's Disease

Read time: 4 min

Congress highlights

Non-motor symptoms – influencing ‘ON’ and ‘OFF’ in Parkinson’s disease

A broad spectrum of non-motor symptoms is highly prevalent in Parkinson’s disease (PD) which...

Depression, Schizophrenia

Read time: 4 min

Congress highlights

Towards new treatment options for MDD and schizophrenia: a role for D2 receptor partial agonists

Major depressive disorder (MDD) and schizophrenia share in common the side effect burden associated...

Read time: 3 min

Treatment-resistant schizophrenia – results of a survey on its clinical impact and therapeutic strategies

The results of an online survey completed by 204 US psychiatrists on the clinical impact of...

Read time: 3 min

Treatment-resistant schizophrenia through the lens of observational databases

Longitudinal medical data of patients in healthcare databases may provide a better understanding of...

Read time: 3 min

Brain circuits in depression and response to pharmacotherapy

The symptoms of major depressive disorder (MDD) vary from patient to patient. The primary treatment...

Alzheimer's Disease

Read time: 3 min

How beneficial is cholinesterase inhibition and for whom?

New evidence suggests that cholinesterase inhibition in prodromal Alzheimer’s disease (AD)...

Read time: 3 min

Steps towards more effective and better tolerated treatment options for schizophrenia

New more effective and better tolerated treatments for schizophrenia are needed to improve patient...

Depression, Schizophrenia

Read time: 3 min

Congress highlights

Why do we need new treatments for major depressive disorder and schizophrenia?

Atypical antipsychotics are the mainstay of treatment for schizophrenia and a therapeutic option as...

Alzheimer's Disease

Read time: 2 min

Addressing challenges of dosage and administration in the development of disease-modifying therapy

Challenges in the development of disease-modifying therapy for Alzheimer’s disease (AD)...

Read time: 4 min

Congress highlights

The promise of big data analysis – precision psychiatry and therapeutic targeting

Psychiatric diagnosis - according to DSM-5 - is largely based on psychiatric symptoms, with a great...

Read time: 3 min

Congress highlights

Treatment-resistant schizophrenia and the impact on caregivers: A focus group study

Treatment-resistant schizophrenia (TRS), clinically defined as failure to respond to two trials of...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country